BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11598040)

  • 1. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
    Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
    Baker CJ; Rench MA; Paoletti LC; Edwards MS
    Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
    J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
    J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
    J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
    Palazzi DL; Rench MA; Edwards MS; Baker CJ
    J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
    Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
    Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
    Baker CJ; Rench MA; McInnes P
    Vaccine; 2003 Jul; 21(24):3468-72. PubMed ID: 12850362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits.
    Paoletti LC; Guttormsen HK; Christian MS; Hoberman AM; McInnes P
    Hum Vaccin; 2008; 4(6):435-43. PubMed ID: 18443428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
    Paoletti LC; Pinel J; Kennedy RC; Kasper DL
    J Infect Dis; 2000 Feb; 181(2):653-8. PubMed ID: 10669351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
    Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
    Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
    Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
    Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
    Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.